Conflicts of Interest: Dr. Roger Cady currently serves on several advisory boards: Allergan, Astellas, MAP Pharmaceuticals, Merck & Co, Inc., Novartis, Ortho-McNeil Neurologics, and Zogenix. He also receives research grants from Allergan, Boston Scientific, Bristol Myers, GlaxoSmithKline, Merck & Co, Inc., OptiNose, PuraMed Bioscience, and Zogenix. Dr. Cady provided consulting services for Allergan, Astellas, GlaxoSmithKline, Merck & Co., Inc., and Ortho-McNeil Neurologics. Dr. Philip O'Carroll has received honoraria from Eli Lilly and Allergan Pharmaceuticals, and grant support from GlaxoSmithKline. Dr. Kent Dexter has nothing to disclose. Dr. Fred Freitag is on the speaker's bureau for Allergan Pharmaceuticals, Nautilus Neuroscience, and Zogenix Pharmaceuticals. He also is an advisory board/consultant for Allergan Pharmaceuticals and MAP Pharmaceuticals, and received grant support from GlaxoSmithKline. Candace L. Shade has nothing to disclose.
SumaRT/Nap vs Naproxen Sodium in Treatment and Disease Modification of Migraine: A Pilot Study
Article first published online: 10 SEP 2013
© 2013 American Headache Society
Headache: The Journal of Head and Face Pain
Volume 54, Issue 1, pages 67–79, January 2014
How to Cite
Cady, R., O'Carroll, P., Dexter, K., Freitag, F. and Shade, C. L. (2014), SumaRT/Nap vs Naproxen Sodium in Treatment and Disease Modification of Migraine: A Pilot Study. Headache: The Journal of Head and Face Pain, 54: 67–79. doi: 10.1111/head.12211
This study was sponsored by a grant from GlaxoSmithKline, Research Triangle Park, North Carolina.
Trial Registration: ClinicalTrials.gov NCT01300546.
Study approved by Sterling IRB.
- Issue published online: 8 JAN 2014
- Article first published online: 10 SEP 2013
- Manuscript Accepted: 4 JUL 2013
- GlaxoSmithKline, Research Triangle Park, North Carolina